https://galimedix.com/press-releases/ 2026-03-19T16:58:22+00:00 https://galimedix.com/article/galimedix-accelerating-development-of-its-next-generation-oral-anti-amyloid-beta-drug-gal-201-for-alzheimers-disease/ 2023-07-21T08:18:33+00:00 https://galimedix.com/article/planned-phase-2-trial-of-visual-function-improvement-in-iamd-gains-support-from-novel-analysis-of-microperimetry-endpoints/ 2023-07-21T08:20:33+00:00 https://galimedix.com/article/galimedix-therapeutics-inc-s-gal-101-gains-from-target-validation-by-positive-phase-3-results-of-biogens-aducanumab/ 2023-07-21T08:20:59+00:00 https://galimedix.com/article/galimedix-therapeutics-inc-appoints-recognized-industry-veteran-alexander-gebauer-m-d-ph-d-as-executive-chairman/ 2023-07-21T08:21:55+00:00 https://galimedix.com/article/galimedix-therapeutics-inc-to-present-at-the-bio-investor-summit/ 2023-07-21T08:22:19+00:00 https://galimedix.com/article/galimedix-therapeutics-inc-to-present-at-ophthalmology-innovation-summit-during-the-american-academy-of-ophthalmology-meeting/ 2023-07-21T08:22:49+00:00 https://galimedix.com/article/preclinical-studies-demonstrate-galimedix-therapeutics-investigational-compound-gal-101-shows-neuroprotective-effect-from-toxic-amyloid-beta-in-dry-amd-and-glaucoma-models/ 2023-07-21T08:23:05+00:00 https://galimedix.com/article/galimedix-inc-appoints-renowned-industry-veteran-and-innovator-in-the-field-of-ophthalmology-thomas-hohman-ph-d-to-board-of-directors/ 2023-07-21T08:23:20+00:00 https://galimedix.com/article/galimedix-therapeutics-to-present-at-the-bio-ceo-investor-conference/ 2023-07-21T08:23:58+00:00 https://galimedix.com/article/galimedix-therapeutics-presents-data-showing-safety-tolerability-and-potential-for-efficacy-of-its-investigational-eyedrops-containing-gal-101-at-glaucoma-360-conference/ 2023-07-21T08:24:54+00:00 https://galimedix.com/article/galimedix-therapeutics-to-participate-in-the-8th-annual-glaucoma-360-conference/ 2023-07-21T08:25:19+00:00 https://galimedix.com/article/galimedix-therapeutics-appoints-industry-veteran-hermann-russ-m-d-ph-d-chief-scientific-officer/ 2023-07-21T08:25:48+00:00 https://galimedix.com/article/new-in-vitro-study-demonstrates-galimedix-therapeutics-investigational-compound-mrz-99030-neutralizes-the-reproduction-of-misfolded-amyloid-beta-thereby-potentially-reducing-synaptotoxic-eff/ 2023-07-21T08:26:22+00:00 https://galimedix.com/article/thea-open-innovation-and-galimedix-announce-strategic-partnership-to-develop-and-commercialize-gal-101-a-phase-2-3-ready-small-molecule-to-treat-ophthalmic-indications-with-high-unmet-medical-need/ 2023-07-30T08:47:44+00:00 https://galimedix.com/article/galimedix-appoints-dr-luciana-summo-as-vice-president-rd-operations/ 2023-10-25T12:28:19+00:00 https://galimedix.com/article/galimedix-therapeutics-announces-new-pre-clinical-data-with-gal-201-in-an-alzheimers-disease-transgenic-model-to-be-presented-at-ad-pd-2024-conference/ 2024-02-29T05:33:06+00:00 https://galimedix.com/article/galimedix-therapeutics-presents-new-scientific-data-showing-promising-neuroprotective-effects-of-gal-201-for-the-treatment-of-alzheimers-disease-at-ad-pd-2024/ 2024-03-08T09:34:37+00:00 https://galimedix.com/article/meitner-humboldt-research-award/ 2024-04-16T07:51:42+00:00 https://galimedix.com/wp-content/uploads/2024/04/Prof._Ehud_Gazit.jpg https://galimedix.com/article/galimedix-therapeutics-establishes-scientific-advisory-board-of-renowned-retina-experts-as-company-prepares-to-enter-phase-2-clinical-study-with-gal-101/ 2024-07-05T08:09:59+00:00 https://galimedix.com/article/galimedix-therapeutics-initiates-phase-1-study-with-oral-small-molecule-gal-101-an-amyloid-beta-a%ce%b2-aggregation-modulator/ 2024-12-05T13:58:10+00:00 https://galimedix.com/article/galimedix-therapeutics-initiates-pivotal-phase-2-study-with-gal-101-eye-drops-in-dry-amd/ 2024-12-23T20:04:01+00:00 https://galimedix.com/article/galimedix-therapeutics-to-present-positive-pre-clinical-data-with-amyloid-beta-aggregation-modulator-in-development-for-oral-alzheimers-disease-treatment-at-ad-pd-2025-conference/ 2025-03-24T14:15:11+00:00 https://galimedix.com/article/galimedix-therapeutics-presents-further-scientific-data-showing-disease-modifying-potential-of-oral-gal-201-in-alzheimers-disease-as-well-as-beneficial-effects-on-synaptic-function-and-neuroi/ 2025-04-01T13:06:08+00:00 https://galimedix.com/article/galimedix-therapeutics-completes-single-ascending-dose-part-of-phase-1-study-with-oral-small-molecule-gal-101-an-amyloid-beta-aggregation-modulator/ 2025-05-06T11:57:15+00:00 https://galimedix.com/article/galimedix-therapeutics-publishes-new-data-in-peer-reviewed-international-journal-of-molecular-sciences-demonstrating-disease-modifying-capability-of-gal-201-in-alzheimers-disease/ 2025-05-21T12:08:40+00:00 https://galimedix.com/article/progress-in-clinical-development-for-alzheimers-and-other-indications-galimedix-therapeutics-successfully-completes-phase-1-study-with-oral-small-molecule-gal-101-an-amyloid-beta-aggregation/ 2025-10-21T11:45:40+00:00 https://galimedix.com/article/galimedix-therapeutics-presents-compelling-phase-1-study-results-showing-excellent-safety-and-pharmacokinetics-with-oral-small-molecule-gal-101-at-ctad-2025/ 2025-12-04T19:15:13+00:00 https://galimedix.com/article/galimedix-therapeutics-to-present-promising-pre-clinical-data-with-next-generation-oral-amyloid-beta-aggregation-modulator-at-ad-pd-2026-conference/ 2026-03-11T10:05:01+00:00 https://galimedix.com/article/galimedix-therapeutics-earns-milestone-payment-in-ophthalmology-partnership-with-thea-open-innovation/ 2026-03-12T12:00:18+00:00 https://galimedix.com/article/galimedix-therapeutics-presents-strong-pharmacokinetic-profile-of-next-generation-oral-alzheimers-candidate-at-ad-pd-2026/ 2026-03-20T07:00:07+00:00